CAJ | 학술논문

多发性骨髓瘤目前仍是无法治愈的恶性血液系统疾病，复发、耐药、治疗相关毒性仍是阻碍患者生存的重要因素。来那度胺是新一代免疫调节剂，具有抗血管生成、改善免疫功能和肿瘤杀伤、改变骨髓微环境等独特的多重的作用机制。来那度胺在复发难治性多发性骨髓瘤的治疗中显著延长了无进展生存期（PFS）和总生存率。在新诊断的多发性骨髓瘤初始治疗中也获得了较高的缓解率。它在巩固维持治疗中更是显著延长了PFS和生存期，为长期“控制”多发性骨髓瘤提供了新的治疗策略。
다발성골수류목전잉시무법치유적악성혈액계통질병，복발、내약、치료상관독성잉시조애환자생존적중요인소。래나도알시신일대면역조절제，구유항혈관생성、개선면역공능화종류살상、개변골수미배경등독특적다중적작용궤제。래나도알재복발난치성다발성골수류적치료중현저연장료무진전생존기（PFS）화총생존솔。재신진단적다발성골수류초시치료중야획득료교고적완해솔。타재공고유지치료중경시현저연장료PFS화생존기，위장기“공제”다발성골수류제공료신적치료책략。
Multiple myeloma(MM) is a malignant plasma disease and remains incurable up to now. The survival of the MM patients is hindered by the factors such as relapse, drug resistance and chemotherapeutic toxicity. Lenalidomide is a new immunomodulatory drugs and had various mechanisms in different hematologic malignancies. These mechanism involve direct cytotoxicity on tumor, immunomodulation, anti-angiogenesis activity and effects on multiple myeloma microenvironment. Lenalidomide could significantly prolong the progression-free survival (PFS) in relapsed and refractory MM. It could attained high remission rate as initial therapy for newly diagnosed MM patients. Lenalidomide had provide a new therapy strategy and possibil ity for long-term control MM due to its effective prolonging survival and PFS as consolidation and maintained therapy.